Salipro Biotech AB, a Swedish biotech company, has entered into a research collaboration and license agreement with Sanofi for the discovery of therapeutic biologics against a challenging drug target.
 
The collaboration leverages Salipro’s expertise in developing stable antigens of GPCRs, ion channels and transporters via its Salipro platform with Sanofi’s discovery programs to identify biologics with the desired therapeutic properties against a selected target.
 
“We are excited to work closely with the innovative team at Sanofi to accelerate their drug discovery efforts against a selected membrane protein drug target,” said Jens Frauenfeld, CEO of Salipro Biotech. “Combining our expertise and platform technology to generate Salipro-stabilized drug targets with Sanofi’s expertise in biologics discovery and development will open up entirely new possibilities to make the undruggable druggable for Sanofi’s biopharmaceutical pipeline.”